Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas-Reference-Cited by-同舟云学术

Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas

Published:2016-12 Issue: Volume:102 Page:42-43
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Gibelin Cécilia,Avrillon Virginie,De La Fouchardiere Arnaud,Mc Leer-Florin Anne,Lantuejoul Sylvie,Fayette Jérôme

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference7 articles.

1. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT);Barlesi;Lancet (London England),2016

2. ALK-rearranged squamous cell lung carcinoma responding to crizotinib: a missing link in the field of non-small cell lung cancer?;Vergne;Lung Cancer (Amsterdam Netherlands),2016

3. Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?;Chiu;Cancer Chemother. Pharmacol.,2014

4. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Reck;Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO,2014

5. BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers;Couraud;Eur. Respir. J.,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients;Genes & Genomics;2022-11-29

2. Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report;Frontiers in Oncology;2021-06-21

3. EML4–ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib;Cancer Chemotherapy and Pharmacology;2018-04-02

4. ALK and ROS1 Double-Rearranged Lung Squamous Cell Carcinoma Responding to Crizotinib Treatment: A Case Report;Journal of Thoracic Oncology;2017-12

5. A patient with classic biphasic pulmonary blastoma harboring CD74–ROS1 fusion responds to crizotinib;OncoTargets and Therapy;2017-12